Abstract
Importance The use of warfarin as an anticoagulant to prevent thromboembolism in patients with infective endocarditis (IE) remains controversial due to potentially increased bleeding risks.
Objective This study compared the risks of ischemic stroke, death and bleeding in patients with IE with and without warfarin use.
Design Prospective cohort study.
Setting Population-based.
Participants Patients aged 18 or older and diagnosed with IE in Hong Kong between January 1st 1997 and August 31st 2020 were included. Patients with use of any anticoagulant 30 days before IE diagnosis were excluded. Patients initiated on warfarin within 14 days of IE diagnosis and patients without warfarin use were matched for baseline characteristics using 1:1 propensity score matching.
Exposure Warfarin use within 14 days of IE diagnosis.
Main outcomes and measures Patients were followed up to 90 days for the outcomes of ischemic stroke, all-cause mortality, intracranial hemorrhage, and gastrointestinal bleeding. Cox regression was used to determine hazard ratios (HRs) [95% confidence intervals (CIs)] between treatment groups. Fine-Gray competing risk regression with all-cause mortality as the competing event was performed as a sensitivity analysis. In addition to 90-day analyses, landmark analyses were performed at 30 days of follow-up.
Results The matched cohort consisted of 675 warfarin users (57.0% male, age 59±16 years) and 675 warfarin non-users (53.5% male, age 61±19 years). From Cox regression, warfarin users had a 50% decreased 90-day risk in all-cause mortality (HR: 0.50 [0.39-0.65]), without significantly different 90-day risks of ischemic stroke (HR: 1.04 [0.70-1.53]), intracranial haemorrhage (HR: 1.25 [0.77-2.04]), and gastrointestinal bleeding (HR: 1.04 [0.60-1.78]). Thirty-day landmark analysis showed similar results. Competing risk regression showed significantly higher 30-day cumulative incidence of intracranial haemorrhage in warfarin users (sub-HR: 3.34 [1.34-8.31]), but not at 90-day (sub-HR: 1.63 [0.95-2.81]). Results from Fine-Gray regression were otherwise congruent with those from Cox regression.
Conclusions and relevance In patients with IE, warfarin use initiated within 14 days of IE diagnosis may be associated with significantly decreased risks of mortality but higher risks of intracranial haemorrhage, with similar risks of ischemic stroke and gastrointestinal bleeding, compared with non-use of warfarin with 14 days of IE diagnosis.
Question Is warfarin, initiated within 14 days of a diagnosis of infective endocarditis (IE), efficacious and safe?
Findings In this propensity score-matched, population-based, prospective cohort study from Hong Kong, warfarin use within 14 days of IE diagnosis was associated with a 50% decrease in the risk of all-cause mortality, albeit with higher risk of intracranial haemorrhage, and without significant differences in the risk of ischaemic stroke and gastrointestinal bleeding.
Meaning In patients with IE, warfarin use within 14 days of diagnosis may have mortality benefits, despite increased risks of intracranial haemorrhage.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
this is not a clinical trial
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was been approved by The Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee and The University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used for analysis in this manuscript are available from the corresponding author upon reasonable request.
Non-standard Abbreviations and Acronyms
- ACE
- Angiotensin-converting enzyme
- CDARS
- Clinical data analysis and reporting system
- CI
- Confidence interval
- DOAC
- Direct oral anticoagulant
- HACEK
- Hemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae
- HR
- Hazard ratio
- H2RA
- Histamine type 2 receptor antagonist
- ICD-9
- International Classification of Diseases, Ninth Revision
- INR
- International normalized ratio
- IE
- Infective endocarditis
- NSAID
- Nonsteroidal anti-inflammatory drug
- OR
- Odds ratio
- PPI
- Proton pump inhibitor
- SD
- Standard deviation
- SHR
- Sub-hazard ratio
- SMD
- Standardized mean difference
- VR
- Variance ratio
